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Abstract
Background: Intradermal vaccination provides direct and potentially more efficient access to the
immune system via specialised dendritic cells and draining lymphatic vessels. We investigated the
immunogenicity and safety during 3 successive years of different dosages of a trivalent, inactivated,
split-virion vaccine against seasonal influenza given intradermally using a microinjection system
compared with an intramuscular control vaccine.
Methods: In a randomised, partially blinded, controlled study, healthy volunteers (1150 aged 18
to 57 years at enrolment) received three annual vaccinations of intradermal or intramuscular
vaccine. In Year 1, subjects were randomised to one of three groups: 3 μg or 6 μg haemagglutinin/
strain/dose of inactivated influenza vaccine intradermally, or a licensed inactivated influenza vaccine
intramuscularly containing 15 μg/strain/dose. In Year 2 subjects were randomised again to one of
two groups: 9 μg/strain/dose intradermally or 15 μg intramuscularly. In Year 3 subjects were
randomised a third time to one of two groups: 9 μg intradermally or 15 μg intramuscularly.
Randomisation lists in Year 1 were stratified for site. Randomisation lists in Years 2 and 3 were
stratified for site and by vaccine received in previous years to ensure the inclusion of a comparable
number of subjects in a vaccine group at each centre each year. Immunogenicity was assessed 21
days after each vaccination. Safety was assessed throughout the study.
Results: In Years 2 and 3, 9 μg intradermal was comparably immunogenic to 15 μg intramuscular
for all strains, and both vaccines met European requirements for annual licensing of influenza
vaccines. The 3 μg and 6 μg intradermal formulations were less immunogenic than intramuscular
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15 μg. Safety of the intradermal and intramuscular vaccinations was comparable in each year of the
study. Injection site erythema and swelling was more common with the intradermal route.
Conclusion: An influenza vaccine with 9 μg of haemagglutinin/strain given using an intradermal
microinjection system showed comparable immunogenic and safety profiles to a licensed
intramuscular vaccine, and presents a promising alternative to intramuscular vaccination for
influenza for adults younger than 60 years.
Trial registration: Clinicaltrials.gov NCT00703651.
Background
Annual influenza epidemics cause substantial morbidity
and mortality in all segments of the population, although
some groups, such as elderly adults and individuals of any
age with certain chronic conditions are especially at risk
[1,2]. Accordingly, international and national guidelines
recommend influenza vaccination primarily for these
groups, as well as for groups such as young children, preg-
nant women, healthcare workers and any person living
with someone at risk [3,4].
In healthy adults younger than 60 or 65 years (the thresh-
old age for the 'elderly' recommendation in most national
recommendations), influenza vaccination coverage
remains low despite being the most cost-effective inter-
vention against annual influenza infection [5]. In a survey
of influenza vaccination coverage and motivations in five
European countries, the vaccination rate in individuals
aged around 14 to 65 years was less than 15% [6]. The
results of this survey also suggested that the availability of
convenient alternative vaccination methods to standard
intramuscular (IM) vaccination would encourage
increased uptake. Intradermal (ID) vaccination might rep-
resent one such alternative method. Due to its ease of
accessibility, recent research for an alternative way of
administering inactivated influenza vaccine has focused
on delivery into the skin, either into or through the epi-
dermis (referred to as epidermal, transcutaneous or
transdermal vaccination) or into the dermis (ID vaccina-
tion) [7,8]. The skin is not only a sensorial organ and a
physical barrier between the body and its environment; it
is also an efficient immunological barrier, screening
invading molecules and particles to stimulate appropriate
immunological responses. It is equipped with popula-
tions of professional antigen presenting cells, including
Langerhans cells in the epidermis and dermal dendritic
cells in the dermis, as well as a network of draining lymph
vessels that start in the dermis [9,10]. Some of the mecha-
nisms of the immune response to an ID injection remain
to be elucidated and depend on multiple factors, includ-
ing the nature of the antigen and the immune status of the
host. It is thought that an ID injection results in two com-
plementary mechanisms for the presentation of antigen
and activation of T-cells in the lymph node: i) the capture
and transport of antigen by dendritic cells in the dermis
(predominantly dermal dendritic cells, although other
cells populations may be recruited to the dermis) to the
draining lymph nodes, and ii) the direct migration of free
antigen through the lymph ducts to the nodes where it is
captured by lymph node resident dendritic cells. It is also
possible that some of the antigen migrates outwards to the
epidermis where it would be captured by Langerhans cells
[11]. ID vaccination delivers antigen directly to this
immune system and has been shown to be effective for a
range of vaccines, including rabies [12-14], hepatitis B
[15-17] and influenza [18-21]. However, to date the use
of this route has been hampered by the lack of appropriate
vaccine delivery systems combining reliability, safety and
simplicity of use. The standard technique to administer
intradermal vaccines such as rabies is difficult to perform
correctly and requires specifically trained and experienced
personnel.
A new microinjection system (Soluvia™, BD, Becton, Dick-
inson and Company, Franklin Lakes, NJ, USA) has been
developed specifically to provide a convenient and relia-
ble ID vaccination that overcomes the technical difficul-
ties associated with historical ID injection methods. This
easy-to-use system features a prefilled, ready-to-use
syringe with micro-needle that protrudes 1.5 mm from
the proximal end of the glass syringe [22]. It has been
shown to result in the consistent and accurate dermal
infiltration of the intended volume of fluid [22].
We report a trial conducted to assess the immunogenicity
and safety of a trivalent, inactivated, split-virion influenza
vaccine given intradermally using the new microinjection
system. Several ID dosages were evaluated in comparison
with a licensed inactivated influenza vaccine given intra-
muscularly. The trial lasted 3 years to investigate the safety
of annual revaccination with the ID vaccine and annual
vaccination alternating between ID and IM routes.
Methods
The study was conducted in five centres in Belgium, one
in the Czech Republic (Years 1 and 2 only) and three cen-
tres in Lithuania between September 2003 and May 2006.
It was approved by the ethics committee of each centreBMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
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before any patients were enrolled at that centre, and was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice. All subjects gave written
informed consent before entering the study.
Study subjects
Healthy volunteers aged 18 to 57 years (that is, <60 years
at Year 3 of the study) were eligible. Exclusion criteria
were: allergies to egg or chicken proteins or any of the vac-
cine constituents; a chronic illness in the active phase;
acute febrile disease within 72 hours of any of the vacci-
nations or an axillary temperature >37.5°C on the day of
vaccination; influenza vaccination within 6 months of the
first study vaccination; any vaccination within 28 days of
each study vaccination; pregnancy or breastfeeding; treat-
ment with immunosuppressive or cancer therapy within 1
month of each vaccination, or an immunoglobulin injec-
tion within 3 months of each vaccination.
Study design
This was a phase II, multicentre, randomised, partially
blinded, dose-ranging study conducted over 3 successive
years to assess the immunogenicity and safety of three
annual vaccinations of ID, trivalent, inactivated, split-vir-
ion influenza vaccine in comparison with a licensed IM
control vaccine. Each year, vaccination of all subjects
occurred over a period of approximately 2 months (Sep-
tember and October). The primary objective of the study
was to demonstrate, after vaccination in the first year of
the study, that an ID vaccination of 3 μg or 6 μg of hae-
magglutinin (HA) per vaccine strain induced a non-infe-
rior immune response compared with the IM control
vaccine for all three vaccine strains. Secondary objectives
included: assessment of compliance with the immuno-
genicity criteria defined in the European Medicines Evalu-
ation Agency (EMEA) Note for Guidance [23], description
of injection site and systemic safety after vaccination, and
assessment on safety of the effect of three (Years 1, 2 and
3) annual ID vaccinations or alternating ID and IM vacci-
nations from year to year.
In Year 1, 1150 subjects were randomised equally into
three groups and received a first injection of either 3 μg or
6 μg of HA/strain intradermally or the IM control vaccine
(15 μg HA/strain). The initial plan was to select either the
3 μg or 6 μg dosage based on the immunogenicity results
from this first year to proceed with in Years 2 and 3. Sub-
jects were to be randomised again in Year 2 and a third
time in Year 3 into two equal groups and receive either the
chosen ID dosage or the IM control vaccine. Statistical
analysis performed with immunogenicity data collected
after Year 1 vaccination showed that neither the 3 μg nor
the 6 μg ID vaccine met the criteria for non-inferiority to
the control IM vaccine. The protocol was therefore
amended to continue vaccination in Years 2 and 3 with an
escalated ID dose of 9 μg of HA/strain. The rationale for
this amendment was two-fold: firstly to obtain descriptive
immunogenicity data in a large sample size with this 9 μg
ID formation before performing a formal assessment of
non-inferiority versus the IM control in a follow-up trial,
and secondly to assess the effect on safety of three annual
ID vaccinations or alternating ID and IM vaccinations
from year to year, as initially planned. This report will
concentrate on the 9 μg vaccine formulation.
Randomisation was performed using a permuted block
randomisation method with decreasing block size. In Year
1, randomisation was stratified by centre. In Year 2, ran-
domisation was stratified by centre and by vaccine actu-
ally received by each subject in Year 1. In Year 3,
randomisation was again stratified by centre and by vac-
cine received actually received in Years 1 and 2. This ran-
domisation strategy ensured that, each year, a comparable
number of subjects were included in each vaccine group
with an equal distribution of subjects vaccinated intrader-
mally or intramuscularly in previous years (Figure 1). An
interactive voice response system via telephone allocated
a dose number to each subject that corresponded to one
of the vaccines. In Year 3, an additional randomisation
identified a subset of subjects who would provide blood
samples for immunogenicity analysis after the third vacci-
nation. The Year 3 blood sampling randomisation list
took into account the route of vaccination used for each
subject in each of the 3 years so that the immunogenicity
subset contained comparable numbers from each combi-
nation of ID and IM vaccination over 3 years (Figure 1). It
was initially planned to have a similar immunogenicity
subset for Year 2. However, as neither of the ID formula-
tions tested in Year 1 met the non-inferiority criteria, the
protocol was amended (and renewed informed consent
obtained) to collect blood from all subjects to compare
the 9 μg ID vaccine with the 15 μg IM formulation. The
study was open-label, except for antigen dosage in the two
ID groups in Year 1, which was double-blind.
Vaccination
Both the investigational ID vaccines and the IM control
vaccine (Vaxigrip®) were trivalent inactivated, split-virion
influenza vaccines (Sanofi Pasteur, Lyon, France). The
antigenic dosage and strain composition of the investiga-
tional ID vaccines and the IM control vaccine given each
year is shown in Table 1. The injected volume was 0.1 ml
for all ID vaccines and 0.5 ml for the IM vaccine. ID vacci-
nation was performed using the microinjection system
described above. All vaccines were given into the deltoid
region.
Immunogenicity outcomes
The primary endpoint was the geometric mean titre
(GMT) of anti-HA antibodies for each of the three influ-BMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
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Randomisation strategy Figure 1
Randomisation strategy. Study subjects were randomised before each of the three vaccinations (represented by arrows): 
included subjects were randomised into three equally sized vaccine groups for the Year 1 vaccination, then in two equally sized 
vaccine groups in each of the subsequent years. Randomisation for vaccination in Years 2 and 3 was stratified for the vaccine 
received in previous years to ensure that a comparable number of subjects were included in each vaccine group. An additional 
Year 3 immunogenicity randomisation list was generated to select randomly a subset of approximately 30 subjects per vaccine 
stratum for blood sampling. Randomisation was also stratified for centre (not illustrated here). N = number of subjects ran-
domised to each group (discontinuations are not represented).
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Table 1: Virus strain composition and antigenic content of each annual influenza vaccine
Vaccine dosage and route* Strain composition
Year 1: Northern Hemisphere 2003–2004 formulation:
3 μg ID or A/New Caledonia/20/99 (H1N1) (A/New Caledonia/20/99-like strain)
6 μg ID or A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like strain)
15 μg IM B/Shandong/7/97 (B/Hong Kong/330/2001-like strain)
Year 2: Northern Hemisphere 2004–2005 formulation:
9 μg ID or A/New Caledonia/20/99 (H1N1) (A/New Caledonia/20/99-like strain)
15 μg IM A/Wyoming/3/2003 (H3N2) (A/Fujian/411/2002-like strain)
B/Jiangsu/10/2003 (B/Shanghai/361/2002-like strain)
Year 3: Southern Hemisphere 2005 formulation:
9 μg ID, or A/New Caledonia/20/99 IVR-116 (H1N1) (A/New Caledonia/20/99-like strain)
15 μg IM A/Wellington/1/2004 IVR-139 (H3N2) (A/Wellington/1/2004-like strain)
B/Jiangsu/10/2003 (B/Shanghai/361/2002-like strain)
*Intradermal (ID) vaccines were formulated to contain 3, 6, 9 μg of haemagglutinin (HA) per strain in a volume of 0.1 ml and administered by 
microinjection; the intramuscular (IM) vaccine was the licensed vaccine Vaxigrip®, containing 15 μg of (HA) per strain in a volume of 0.5 ml.BMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
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enza strains 21 days after the first vaccination in each
group. Antibody titres were determined in duplicate
simultaneously for each strain before and 21 days after
vaccination by the HA inhibition assay using the strains
included in the vaccine each year [24] and are presented
as the highest reciprocal dilution which induced complete
HA inhibition. Strain-specific GMTs were also determined
before and 21 days after the second and third vaccinations
in each group (Table 1). Immunogenicity was further
assessed by calculating the following for each strain in
each group: geometric mean ratio of post-vaccination titre
to pre-vaccination titre (GMTR); seroprotection rate (per-
centage of subjects with a post-vaccination titre ≥ 40); and
seroconversion or significant titre increase rate (post-vac-
cination titre ≥ 40 in subjects with a pre-vaccination titre
<10 or a ≥ 4-fold increase in titre after vaccination in sub-
jects with a pre-vaccination titre ≥ 10). Compliance with
the immunogenicity criteria for people aged 18 to 60 years
outlined in the EMEA Note for Guidance was determined.
The EMEA recommendations are that at least one of the
following criteria should be met for each strain: GMTR ≥
2.5, seroprotection rate >70%, and seroconversion or sig-
nificant increase rate >40% [23].
Safety outcomes
The following solicited reactions based on the EMEA Note
for Guidance [23], occurring within 3 days of each vacci-
nation were recorded: injection site induration >5 cm for
more than 3 days, injection site bruising, fever (axillary
body temperature increased by >37.5°C and lasting ≥ 24
hours), malaise and shivering. Additionally, subjects
recorded the occurrence of any solicited injection site
reactions (pain, pruritus and any of the following of at
least 0.5 cm in diameter: redness, induration, oedema and
bruising) and systemic reactions (axillary temperature
>37.5°C, asthenia, headache, arthralgia, myalgia, rigors,
sweating and malaise) within 7 days of vaccination. Safety
results are also presented according to vaccination history
during the study. Details of any serious adverse events
(SAEs) were collected up to 6 months after the last vacci-
nation.
Statistical methods
Assuming a standard deviation of 0.67 for the difference
in log-transformed GMTs, it was calculated that 344 sub-
jects per group were necessary to show non-inferiority
(that is, a minimum acceptable post-vaccination GMT
ratio [ID/IM] of 1/1.5) with a global power of 80.4%
(93% for the individual test for each strain) and a signifi-
cance level of 5%. To allow for 10% of subjects not being
evaluable, 1146 subjects were to be included, 382 in each
group.
All statistical analyses were performed using SAS software,
version 8.2 (SAS Institute, Cary, NC, USA). The primary
endpoint was analysed to determine whether the ID vac-
cine was non-inferior to IM vaccination. For both ID vac-
cine doses used in the first year, the ratio of GMTs after the
first vaccination (ID/IM) and their 95% confidence inter-
vals (CI) were calculated for each strain. To conclude non-
inferiority of the ID vaccine, the lower bound of the 95%
CI had to be greater than 1/1.5 for each strain. This analy-
sis was performed, as planned in the protocol, on data col-
lected from all study participants after the first vaccination
and was performed with the aim of selecting one of the
two ID vaccine formulations for further analysis in Years
2 and 3. If both the 3 μg and 6 μg ID vaccines had been
found to be non-inferior to the IM control, then the lower
of the two would have been selected. The ratio of GMTs
(ID/IM) and their 95% CIs were also calculated to com-
pare the immunogenicity of the ID 9 μg vaccine with the
IM 15 μg vaccine after the second vaccination. 95% CIs
were calculated for all immunogenicity outcomes using
the normal approximate method for GMTs and GMTRs
and using the Clopper-Pearson method for single percent-
ages [25]. Safety outcomes are presented descriptively.
The primary analysis in Year 1 included all subjects who
had conformed with the protocol and according to vac-
cine group allocation (per protocol analysis). Immuno-
genicity analysis after each vaccination was carried out on
all subjects who had received all vaccinations up to that
point and for whom pre- and post-vaccination titres were
available. Safety analysis was performed on all available
data.
Results
Subjects
Of the 1150 subjects enrolled and randomised, 1149 were
vaccinated in Year 1, 1091 were re-randomised and vacci-
nated in Year 2, and 828 were re-randomised and vacci-
nated in Year 3 (Figure 2).
One subject was withdrawn before completing the first
part of the study due to an SAE unrelated to vaccination
(hospitalisation for a chronic psychiatric condition). Four
subjects died during the study; cause of death hepatocel-
lular carcinoma, myosarcoma of the left thigh adductor,
cerebral haemorrhage and myocardial infarction (98
other subjects experienced an SAE during the 3 years of
the study). None were related to vaccination.
Groups were equally matched in terms of both age and sex
ratio; more women than men were enrolled (Table 2).
Immunogenicity
The 6 μg ID vaccination induced an immune response
that satisfied the EMEA immunogenicity criteria (all crite-
ria met for all strains, except the seroprotection and sero-
conversion rates for the B strain) (Table 3). However,BMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
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Study flow chart Figure 2
Study flow chart. ID, intradermal; IM, intramuscular; N, number of subjects. *As one of the study centres (the Czech centre) 
did not participate in the third part of the study, a large number of subjects were discontinued from the study between the sec-
ond and third vaccinations.
 
ID 3   μ  g 
n = 384 
ID 6   μ  g 
n = 383 
IM 15 μg
n = 382
IM 15 μg
n = 547
ID 9   μ  g 
n = 544 
ID 9   μ  g 
n = 418 
IM 15 μg
n = 410
382 completed 
1 voluntary withdrawal 
1 lost to follow -up
381 completed
1 voluntary withdrawal
1 SAE
380 completed
2 voluntary withdrawal
541 completed 
2 lost to follow -  up 
1 other reason 
545 completed
2 lost to follow -up
Not
randomised
or injected
n = 4
Withdrew between 
2nd and 3rd 
vaccination 
n = 254*
Not
randomised
or injected
n = 4
Available for 2nd  
vaccination  
n = 1095 
Available for 3rd  
vaccination  
n = 832 
409 completed
1 lost to follow -up
Withdrew between 
1st and 2nd 
vaccination 
n = 48
417 completed 
1 lost to follow -  up 
Enrolled and  
randomised 
N = 1150 
Withdrew 
before 
vaccination
n = 1
Year 1 
Year 2 
Year 3 
ID 3   μ  g 
n = 384 
ID 6   μ  g 
n = 383 
IM 15 μg
n = 382
IM 15 μg
n = 547
ID 9   μ  g 
n = 544 
ID 9   μ  g 
n = 418 
IM 15 μg
n = 410
382 completed 
1 voluntary withdrawal 
1 lost to follow -up
381 completed
1 voluntary withdrawal
1 serious adverse event
380 completed
2 voluntary withdrawal
541 completed 
2 lost to follow -  up 
1 other reason 
545 completed
2 lost to follow -up
Not
randomised
or injected
n = 4
Withdrew between 
2nd and 3rd 
vaccination 
n = 254*
Not
randomised
or injected
n = 4
Available for 2nd  
vaccination  
n = 1095 
Available for 3rd  
vaccination  
n = 832 
409 completed
1 lost to follow -up
Withdrew between 
1st and 2nd 
vaccination 
n = 48
417 completed 
1 lost to follow -  up 
Enrolled and  
randomised 
N = 1150 
Withdrew 
before 
vaccination
n = 1
Year 1 
Year 2 
Year 3 BMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
Page 7 of 15
(page number not for citation purposes)
neither the 3 μg ID nor the 6 μg ID formulations met the
pre-defined non-inferiority criteria. The lower boundary
of the 95% CI for the ratio of post-vaccination GMTs (ID/
IM) was lower than 1/1.5 in both ID vaccine groups for
each strain (data not shown). Post-vaccination GMTs were
lower in the ID vaccine groups than in the IM vaccine
group for all three strains.
After the second vaccination in Year 2, the immune
responses against all strains were comparable with the 9
μg ID and control vaccine and all EMEA criteria were met
for all strains in both groups (Table 3). For each strain, the
GMT ratio between the ID and IM groups was close to 1
with a narrow 95% CI (A/H1N1: 0.94 [0.81; 1.09], A/
H3N2: 0.98 [0.86; 1.12], B: 0.97 [0.83; 1.14]). Similarly,
comparable results between the two groups were obtained
after the Year 3 vaccination for the subset assessed. In both
groups, all three EMEA criteria were met for the A/H3N2
strain, and the seroprotection criterion was met for the A/
H1N1 and B strains.
Safety
After vaccination in Years 1, 2 and 3, the incidence of
EMEA-specified reactions, most commonly shivering and
malaise, was comparable between groups (Table 4). Con-
sidering the incidence of these reactions after Years 2 and
3 vaccinations in relation to the vaccination route in Years
1 and 2, prior vaccination route was seen to have no
apparent effect on reactogenicity in subsequent years. In
Year 3, the incidence of EMEA reactions did not differ sub-
stantially between all sub-groups, that is, it did not
depend on whether previous vaccinations had been via ID
or IM routes. Notably, one or two previous ID vaccina-
tions did not increase the reactogenicity to ID vaccination
in Year 3 (in comparison with those subjects who had
been vaccinated with the IM control vaccine in the first 2
years). Nor did prior ID vaccination increase the reac-
togenicity of the IM vaccine in Year 2 or 3. Similar results
were obtained when considering the incidence of solicited
injection site and systemic reactions within 7 days of vac-
cination in each subgroup (data not shown).
Solicited reactions within 7 days of vaccination in Years 2 
and 3
Injection site pain and bruising occurred at a comparable
rate in each group after vaccination with 9 μg ID or the
control vaccine in Years 2 and 3 (Table 5). Other solicited
injection site reactions, particularly erythema, were more
frequent with 9 μg ID than with the IM control. Erythema
was the most common local reaction with ID vaccination,
typically appearing within 3 days of vaccination and
resolving spontaneously within 7 days. Injection site reac-
Table 2: Demographic and baseline characteristics
Year 1
3 μg ID
(N = 378)
6 μg ID
(N = 375)
15 μg IM
(N = 376)
Total
(N = 1129)
Mean age ± standard deviation 39 ± 11 39 ± 12 39 ± 12 39 ± 12
Male/female ratio 0.6 0.7 1.0 0.7
History of influenza vaccination*, n (%) 112 (29.6) 114 (30.4) 100 (26.6) 326 (28.9)
Reaction to previous influenza vaccination*, n (%) 10 (8.9) 9 (7.9) 7 (7.0) 26 (8.0)
Year 2
9 μg ID
(N = 544)
15 μg IM
(N = 547)
Total
(N = 1091)
mean age +/- standard deviation 40 ± 12 40 ± 12 40 ± 11
Male/female ratio 0.7 0.7 0.7
Year 3
9 μg ID
(N = 417)
15 μg IM
(N = 411)
Total
(N = 828)
mean age +/- standard deviation 41 ± 11 40 ± 11 40 ± 11
Male/female ratio 0.8 0.7 0.7
Data are for the per protocol population for Year 1 and the safety population for Years 2 and 3. ID, intradermal; IM, intramuscular; N and n, 
number of subjects
*Subjects who recalled having previously received an influenza vaccination and having experienced any reactions after a previous influenza 
vaccination.B
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Table 3: Comparison of immunogenicity results after intradermal or intramuscular vaccination
European Medicines 
Evaluation 
Agency criteria
A/H1N1 A/H3N2 B
Vaccine received in 
Year 1
3 μg ID 6 μg ID 15 μg IM 3 μg ID 6 μg ID 15 μg IM 3 μg ID 6 μg ID 15 μg IM
Geometric mean titre 
(95% CI)
- 93.6 (78.5;112) 110 (90.5;133) 206 (177;239) 132 (117;149) 156 (137;178) 300 (266;337) 19.2 (17.1;21.5) 21.7 (19.3;24.5) 40.8 (36.1;46.2)
Seroprotection rate*, 
% (95% CI)
>70 72.7 (67.9;77.1) 71.3 (66.5;75.8) 87.1 (83.3;90.3) 88.5 (84.9;91.5) 88.2 (84.5;91.3) 96.9 (94.6;98.4) 28.5 (23.9;33.3) 32.9 (28.1;37.9) 55.7 (50.5;60.8)
Seroconversion†/
significant increase 
rate‡, % (95% CI)
>40 53.1 (48.0;58.2) 55.1 (50.0;60.1) 75.0 (70.3;79.3) 35.4 (30.6;40.4) 43.0 (38.0;48.2) 63.8 (58.7;68.6) 21.0 (17.0;25.5) 27.3 (22.8;32.1) 47.7 (42.6;52.9)
Geometric mean titre 
ratio (post-/pre-
vaccination) (95% CI)
2.5 7.32 (6.16;8.7) 8.38 (6.94;10.1) 17.4 (14.7;20.5) 3.48 (3.02;4.01) 4.19 (3.58;4.90) 9.11 (7.71;10.8) 2.38 (2.13;2.67) 2.73 (2.42;3.07) 4.97 (4.37;5.67)
Vaccine received in 
Year 2
9 μg ID 15 μg IM 9 μg ID 15 μg IM 9 μg ID 15 μg IM
Geometric mean titre 
(95% CI)
- 180 (161; 202) 192 
(174; 212)
380 (343; 420) 386 
(355; 420)
80.6 (71.6; 90.7) 83.1 
(74.8; 92.3)
Seroprotection rate*, 
% (95% CI)
>70 90.0 (87.1; 92.4) 93.4 
(90.0; 95.3)
97.2 (95.4; 98.4) 99.4 
(98.4; 99.9)
73.0 (69.1; 76.8) 74.4 
(70.5; 78.0)
Seroconversion†/
significant increase 
rate‡, % (95% CI)
>40 43.0 (38.8; 47.3) 45.7 
(41.4; 50.0)
53.1 (48.8; 57.4) 50.8 
(46.5; 55.1)
63.4 (59.2; 67.5) 66.6 
(62.5; 70.6)
Geometric mean titre 
ratio (post-/pre-
vaccination) (95% CI)
2.5 4.3 (3.8; 4.8) 4.7 
(4.2; 5.3)
4.4 (4.0; 5.0) 4.4 
(3.9; 5.0)
7.8 (7.0; 8.8) 8.3 
(7.5; 9.1)B
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Vaccine received in 
Year 3
9 μgID 15 μgIM 9 μgID 15 μgIM 9 μgID 15 μgIM
Geometric mean titre 
(95% CI)
- 127 (103; 158) 117.8 
(92.7; 149.6)
415 (337; 510) 300 
(242; 373)
91.0 (74.5; 111.1) 86.2 
(68.4; 108.7)
Seroprotection rate*, 
% (95% CI)
>70 90.7 (83.6; 95.5) 91.3 
(84.2; 96.0)
100 (96.6; 100) 99.0 
(94.8; 100.0)
83.3 (74.9; 89.8) 81.4 
(72.4; 88.4)
Seroconversion†/
significant increase 
rate‡, % (95% CI)
>40 14.8 (8.7; 22.9) 18.3 
(11.4; 27.1)
60.2 (50.3; 69.5) 45.2 
(35.4; 55.3)
24.1 (16.4; 33.3) 19.6 
(12.4; 28.6)
Geometric mean titre 
ratio (post-/pre-
vaccination) (95% CI)
2.5 2.0 (1.7; 2.4) 2.1 
(1.7; 2.5)
4.6 (3.8; 5.6) 3.5 
(2.8; 4.4)
2.3 (1.9; 2.7) 2.3 
(1.9; 2.8)
CI, confidence interval; ID, intradermal; IM, intramuscular.
*Defined as antibody titre ≥ 40; †for subjects with a titre <10 on day 0, defined as a post-injection titre ≥ 40; ‡for subjects with a titre ≥ 10 on day 0, defined as a ≥ 4-fold increase in titres. Data are from the 
other immunogenicity (OI) population.
Table 3: Comparison of immunogenicity results after intradermal or intramuscular vaccination (Continued)B
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Table 4: Safety summary: number of subjects with European Medicines Evaluation Agency -specified reactions after each intradermal and intramuscular vaccination according to vaccine 
history during the study
Year 1
3 μg ID (N = 384) 6 μg ID (N = 383) 15 μg IM (N = 382)
≥ 1 EMEA 
reaction, n (%)
38 (9.9) 39 (10.2) 50 (13.1)
Injection site 
induration*
0 0 1 (0.3)
Injection site 
ecchymosis 
(bruising)
2 (0.5) 1 (0.3) 7 (1.8)
Fever† 4 (1.0) 5 (1.3) 6 (1.6)
Malaise 12 (3.1) 17 (4.4) 19 (5.0)
Shivering 
(rigors)
26 (6.8) 26 (6.8) 21 (5.5)
Year 2 (vaccine history and group)
ID/ID (N = 363) IM/ID (N = 181) ID total (N = 544) ID/IM (N = 363) IM/IM (N = 184) IM total (N = 
547)
≥ 1 EMEA 
reaction, n (%)
41 (11.3) 20 (11.0) 61 (11.2) 39 (10.7) 28 (15.2) 67 (12.2)
Injection site 
induration*
000 000B
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Injection site 
ecchymosis 
(bruising)
5 (1.4) 2 (1.1) 7 (1.3) 7 (1.9) 3 (1.6) 10 (1.8)
Fever† 3 (0.8) 2 (1.1) 5 (0.9) 3 (0.8) 0 3 (0.5)
Malaise 19 (5.2) 8 (4.4) 27 (5.0) 17 (4.7) 15 (8.2) 32 (5.9)
Shivering 
(rigors)
27 (7.4) 9 (5.0) 36 (6.6) 23 (6.3) 18 (9.8) 41 (7.5)
Year 3 (vaccine history and group)
ID/ID/ID 
(N = 137)
IM/ID/ID 
(N = 71)
ID/IM/ID 
(N = 138)
IM/IM/ID
(N = 72)
ID total 
(N = 418)
ID/ID/IM 
(N = 132)
IM/ID/IM 
(N = 72)
ID/IM/IM 
(N = 134)
IM/IM/IM 
(N = 72)
IM total 
(N = 410)
≥ 1 EMEA 
reaction, n (%)
13 (9.5) 11 (15.5) 19 (13.8) 11 (15.3) 54 (12.9) 18 (13.6) 6 (8.3) 13 (9.7) 10 (13.9) 47 (11.5)
Injection site 
induration*
00000 00000
Injection site 
ecchymosis 
(bruising)
4 (2.9) 3 (4.2) 2 (1.4) 4 (5.6) 13 (3.1) 3 (2.3) 1 (1.4) 3 (2.2) 4 (5.6) 11 (2.7)
Fever† 3 (2.2) 1 (1.4) 3 (2.2) 0 7 (1.7) 1 (0.8) 0 0 1 (1.4) 2 (0.5)
Malaise 3 (2.2) 5 (7.0) 6 (4.3) 2 (2.8) 16 (3.8) 9 (6.8) 1 (1.4) 6 (4.5) 4 (5.6) 20 (4.9)
Shivering 
(rigors)
8 (5.8) 4 (5.6) 12 (8.7) 7 (9.7) 31 (7.4) 11 (8.3) 4 (5.6) 6 (4.5) 5 (6.9) 26 (6.3)
Data are from the safety population. EMEA, European Medicines Evaluation Agency; ID, intradermal; IM, intramuscular; n, number of subjects reporting the event; N, number of subjects in the subgroup.
*>5 cm for more than 3 days; †axillary temperature >37.5°C for ≥ 24 hours.
Table 4: Safety summary: number of subjects with European Medicines Evaluation Agency -specified reactions after each intradermal and intramuscular vaccination according to vaccine 
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Table 5: Summary of solicited injection site and systemic reactions within 7 days of intradermal or intramuscular influenza 
vaccination
Year 2 Year 3
9 μgID
(N = 544)
15 μg IM
(N = 547)
9 μg ID
(N = 418)
15 μg IM (N = 410)
Solicited injection site reactions, n (%) 420 (77.2) 253 (46.3) 317 (75.8) 186 (45.5)
Erythema
>0.5 cm 378 (69.5) 53 (9.7) 274 (65.6) 50 (12.2)
>5 cm 29 (5.4) 3 (0.6) 25 (6.0) 2 (0.5)
Induration
>0.5 cm 212 (39.0) 47 (8.6) 166 (39.7) 49 (12.0)
>5 cm 7 (1.3) 2 (0.4) 2 (0.5) 2 (0.5)
Oedema
>0.5 cm 233 (42.8) 28 (5.1) 150 (35.9) 33 (8.0)
>5 cm 9 (1.7) 2 (0.4) 7 (1.7) 2 (0.5)
Bruising
>0.5 cm 10 (1.8) 10 (1.8) 14 (3.3) 13 (3.2)
>5 cm 0 1 (0.2) 1 (0.2) 2 (0.5)
Pain
any grade 204 (37.5) 214 (39.1) 180 (43.1) 152 (37.1)
grade 3 3 (0.6) 2 (0.4) 5 (1.2) 4 (1.0)
Pruritus
any grade 172 (31.6) 39 (7.1) 121 (28.9) 31 (7.6)
grade 3 3 (0.6) 1 (0.2) 6 (1.4) 1 (0.2)
Solicited systemic reactions, n (%) 155 (28.5) 181 (33.1) 123 (29.4) 101 (24.6)
Pyrexia
>37.5°C 8 (1.5) 5 (0.9) 10 (2.4) 2 (0.5)
>38.5°C 0 0 2 (0.5) 1 (0.2)
Asthenia
any grade 97 (17.8) 108 (19.7) 75 (17.9) 52 (12.7)
grade 3 11 (2.0) 6 (1.1) 8 (1.9) 6 (1.5)
Headache
any grade 88 (16.2) 82 (15.0) 69 (16.5) 57 (13.9)
grade 3 7 (1.3) 4 (0.7) 3 (0.7) 3 (0.7)
Arthralgia
any grade 31 (5.7) 33 (6.0) 26 (6.2) 8 (2.0)
grade 3 1 (0.2) 2 (0.4) 2 (0.5) 0
Myalgia
any grade 40 (7.4) 84 (15.4) 47 (11.2) 41 (10.0)
grade 3 1 (0.2) 4 (0.7) 2 (0.5) 2 (0.5)
Rigors
any grade 41 (7.5) 44 (8.0) 35 (8.4) 31 (7.6)
grade 3 1 (0.2) 3 (0.6) 3 (0.7) 1 (0.2)
Increased sweating
any grade 35 (6.4) 39 (7.1) 28 (6.7) 25 (6.1)
grade 3 2 (0.4) 2 (0.4) 0 2 (0.5)
Malaise
any grade 31 (5.7) 37 (6.8) 18 (4.3) 22 (5.4)
grade 3 3 (0.6) 4 (0.7) 2 (0.5) 1 (0.2)
Data are from the safety population. ID, intradermal; IM, intramuscular; n, number of subjects reporting the event; N, number of subjects in the 
subgroup; %, n/(N minus the number of subjects with missing data for the given variable).
Pain: Grade 1: mild/well tolerated, Grade 2: moderate/hindering movement, Grade 3 pain: preventing normal daily activity. Pruritus: Grade 1: mild/
occasional, Grade 2: moderate/frequent, Grade 3 severe/continuous. Asthenia, headache, arthralgia, myalgia, rigors, increased sweating, malaise: 
Grade 1: symptom present but well tolerated, Grade 2: symptom interfered with normal daily activities, Grade 3 symptom prevented normal daily 
activities.BMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
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tions were mostly mild or moderate: 90% of all injection
site reactions observed with 9 μg ID and 96% with the IM
control were mild to moderate. In particular, after each
vaccination no more than six subjects (1.4%) per group
reported severe pain, defined as 'pain preventing normal
daily activity', or pruritus, defined as 'continuous pruritus'
(other injection site reactions were considered severe if
they measured more than 5 cm in diameter). The 9 μg ID
and the control vaccine caused comparable numbers of
solicited systemic reactions, the most frequent of which
were asthenia and headache (Table 5). Grade 3 or 'severe'
(defined as 'preventing normal daily activity') systemic
reactions concerned no more than 4% of subjects vacci-
nated intradermally and 2.7% or less of subjects vacci-
nated intramuscularly. These reactions typically occurred
within 3 days of vaccination and spontaneously resolved
within 3 days.
Discussion
The primary aim of this study was to identify the HA dose
that, when administered intradermally using a microin-
jection system, would elicit an immune response that is
statistically non-inferior to that elicited by a standard IM
vaccination of 15 μg of HA/strain. In line with previous
observations [19,20,26], ID vaccination with either 3 μg
or 6 μg of HA was immunogenic and, in the case of the 6
μg vaccine, sufficiently immunogenic to comply with the
EMEA immunogenicity recommendations [23]. However,
antibody responses to 6 μg were lower than with the
standard IM vaccine and non-inferiority was not demon-
strated. These results are consistent with those of a large
study in healthy adults (20 to 50 years), in which a
reduced-dose ID influenza vaccination led to inferior anti-
body responses compared with a standard IM vaccine,
despite meeting the EMEA requirements [26]. Two
smaller studies have shown comparable immunogenicity
of reduced-dose ID influenza to full-dose IM vaccines in
adults aged between 18 and either 40 or 60 years [19,20].
In our study, as non-inferiority was not demonstrated
with either 3 μg or 6 μg of HA, we amended the protocol
to continue vaccination in Years 2 and 3 with an escalated
ID dose of 9 μg of HA/strain. This allowed the immuno-
genicity of this higher dose to be evaluated descriptively in
preparation for a follow-up study that would be needed to
repeat the formal non-inferiority analysis for such an esca-
lated dose.
Despite the lower antigen content, the ID 9 μg vaccine was
comparably immunogenic to the reference IM vaccine,
satisfying EMEA criteria for all three virus strains.
Although this study did not compare the same dosage
given by ID and IM routes, these results are consistent
with previous studies with rabies, hepatitis B and influ-
enza vaccines that support the higher immunogenicity of
the ID vaccination route [13-17]. In a recently reported
study of an investigational ID influenza for elderly adults,
an ID vaccination with 15 μg of HA per strain was shown
to elicit significantly higher immune responses than the
IM vaccination, also with 15 μg HA per strain [27]. The ID
vaccine evaluated in elderly adults by Holland et al. [27]
was manufactured by Sanofi Pasteur (the manufacturers
of the vaccines tested in our study), was administered
using the same microinjection system, and was studied in
comparison with the same control vaccine (Vaxigrip®) as
in our study.
Reactogenicity of the ID vaccine was comparable to that of
the IM vaccine in terms of both EMEA reactions and solic-
ited systemic reactions. It should be noted that the reac-
tions listed in the EMEA Note for Guidance were
specifically designed to determine the reactogenicity of IM
vaccines and, as such, may not be fully appropriate for
assessing reactogenicity after ID vaccination [23]. As
would be expected with a vaccine injected into the skin in
comparison with an injection deep into the muscle, recip-
ients of the ID vaccine more frequently reported local
reactions at the injection site within 7 days of vaccination,
particularly erythema. Importantly, these reactions were
not associated with an increased incidence of injection
site pain. Other studies have also shown increased local
inflammation (mainly erythema and induration) to ID
influenza vaccination compared with IM vaccination, but
with a similar or lower incidence of injection site pain
[19,20,26]. This increase in local reactions is linked to the
underlying inflammatory or immunological response in
the skin, which is more visible with ID than IM vaccina-
tion.
It has been proposed that delivery of antigen via the ID
route and associated activation of dermal dendritic cells
favours the induction of a Th1-type cellular immune
response, which can lead to delayed-type hypersensitivity
[28,29]. Repeated ID vaccination may, therefore, increase
the risk of delayed-type hypersensitivity local reactions. In
a study of a hepatitis B vaccine, secondary systemic or
local reactions were more frequent with a mixed vaccine
schedule (IM followed by ID or vice versa) than either an
IM/IM or an ID/ID schedule [30]. In our study, the safety
profile after three ID vaccinations appeared similar to that
after a single ID vaccination, suggesting that influenza ID
vaccination can be repeated annually without increasing
reactogenicity. Furthermore, interchanging the IM and ID
vaccines from one year to the next did not adversely affect
the safety profile.
Despite the documented health and economic burden of
influenza disease in adults younger than 60 years [31-34],
surveys show that vaccine uptake is lower than the target
coverage rates of between 50% to 90% set by national and
international health organisations [35-37]. Coverage ratesBMC Medicine 2009, 7:13 http://www.biomedcentral.com/1741-7015/7/13
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of as low as 10% have been reported among Western
European adults aged 20 to 40 years, with slightly higher
rates, 15% to 20%, in adults aged 40 to 60 years [38].
These rates are comparable with those reported in the
USA, as well as in countries in Asia, Latin America and
Eastern Europe [39,40]. Several studies have investigated
why vaccine uptake remains low. In two recent reports
from Europe and the USA, 14% to 16% of individuals
questioned cited a dislike of needles and injections as one
of the reasons (although not the primary reason) for not
getting vaccinated [38,41]. This finding suggests that alter-
native vaccination methods that do not use a classic
syringe and needle have the potential to contribute to
increase vaccination coverage among such populations.
The ID vaccine investigated in our study may represent
such an alternative method. This vaccine used a newly
developed microinjection system designed as an easy-to-
use system with a very narrow, 1.5 mm long needle that is
inserted perpendicularly into the skin to accurately inject
antigen into the dermis [22]. This ID influenza vaccine
thus provides an alternative to IM vaccine for adults
younger than 60 years that is convenient for the health-
care provider and may contribute to increase vaccine
uptake in this population.
As the primary outcome was not met in the first year of the
study, our findings are limited by the fact that the immu-
nogenicity of the 9 μg ID vaccine was descriptively com-
pared with the IM vaccine after the second and third
vaccinations. A formal statistical comparison of the 9 μg
ID vaccine dose to the IM vaccine was not possible, as the
population was not representative of an ID vaccination-
naïve population. This formal comparison was done in a
second trial that has been reported separately [42]. These
trials formed part of a marketing authorisation applica-
tion, which has been approved by the European Commis-
sion and will be marketed in the European Union under
the trade names Intanza® and IDflu®.
Conclusion
We have shown that a reduced dose, 9 μg/strain, of triva-
lent, inactivated, split-virion, seasonal influenza vaccine
in a lower injection volume given intradermally using a
novel microinjection system is as immunogenic as con-
ventional IM vaccine with a comparable safety profile.
Furthermore, our results show that the ID vaccine can be
re-administered or interchanged with the IM vaccine
annually without adversely affecting the safety profile.
This vaccine administered using microinjection presents a
promising alternative to IM vaccine for the vaccination of
adults younger than 60 years against seasonal influenza.
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